Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €0.28 EUR
Change Today -0.002 / -0.70%
Volume 0.0
LYF On Other Exchanges
As of 2:08 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

ekf diagnostics holdings plc (LYF) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/21/14 - €0.36
52 Week Low
01/20/15 - €0.24
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

ekf diagnostics holdings plc (LYF) Related Businessweek News

No Related Businessweek News Found

ekf diagnostics holdings plc (LYF) Details

EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East and Africa, and internationally. It offers glycated hemoglobin (HbA1c) analyzers, such as Quo-Test, Quo-Lab, and Biosen HbA1c analyzers for monitoring diabetes. The company also provides hemoglobin analyzers, including Hemo Control, a hemoglobin analyzer that provides quantitative lab quality results within 25 seconds for blood banks, hospitals, and clinics; Hemo Vet for veterinary use; STAT-Site, a hand-held hemoglobin analyzer; UltraCrit, a hematocrit measurement device for blood donor screening; HemataSTAT, a microhematocrit system, which offers quantitative hematocrit; and DiaSpect Hemoglobin T and DiaSpect Tm, the hemoglobin measurement systems. In addition, it offers glucose analyzers, such as C-Line GP+, C-Line Clinic, and S-Line Lab+ used in laboratories and sports institutions; and lactate analyzers comprising Biosen C-Line and S-Line glucose and lactate analyzers, as well as Lactate Scout+, a blood lactate analyzer for athletes, coaches, amateurs, and sport scientists. Further, the company provides rapid testing services, including pregnancy tests, such as True20 and QuPID for urine only or urine and serum pregnancy testing; and infectious diseases tests, such as H. Pylori, RELY Mono, RELY, and Strep A for the detection of pathonogenic micro-organisms, such as bacteria, parasites, viruses, and fungi. Additionally, it offers Sepsis testing services; clinical chemistry reagents; and diagnostic biomarker-based enzyme-linked immunosorbent assay kits and rapid tests, as well as maternal and women health diagnostic solutions. The company sells its products to GP surgeries, pharmacies, blood banks, sports clinics, hospitals, and laboratories through a network of distributors. EKF Diagnostics Holdings plc was founded in 1990 and is headquartered in Cardiff, the United Kingdom.

395 Employees
Last Reported Date: 03/16/15
Founded in 1990

ekf diagnostics holdings plc (LYF) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 238.0K GBP
Executive Chairman
Total Annual Compensation: 45.0K GBP
Chief Financial Officer, Finance Director, Se...
Total Annual Compensation: 167.0K GBP
Chief Operating Officer and Executive Directo...
Total Annual Compensation: 184.0K GBP
Chief Technology Officer and Executive Direct...
Total Annual Compensation: 182.0K GBP
Compensation as of Fiscal Year 2014.

ekf diagnostics holdings plc (LYF) Key Developments

Strategic Review Of Point-Of-Care Business Results In Another Proposal

Further to EKF Diagnostics Holdings plc's (AIM:EKF) announcements dated August, 18, 2015, EKF Diagnostics announces that it has now received a second non-binding preliminary proposal from an unrelated third party to offer $115 million - $125 million in cash for its Point-of-Care business (which excludes the Clinical Chemistry and Molecular Diagnostics businesses). The strategic review previously resulted inter-alia in a non-binding preliminary proposal of $110 million, on a cash free debt free basis, for our Point-of-Care business.

EKF Diagnostics Holdings plc Provides Earnings Guidance for the Six Months Ended June 30, 2015

EKF Diagnostics Holdings plc expected its results for the first half of 2015 to show unaudited revenues of £16.8 million, around the same level as last year, despite not having materially benefited from any tender wins in the current period. Unaudited adjusted EBITDA for the period will be around £0.7 million (in the first half of 2014: £2.2 million). This reduced level of earnings reflects the continuing impact of the investment in its Molecular division.

EKF Diagnostics Holdings plc Announces the Launch of Next Generation Sequencing Technology Precisionpath in Partnership with Greenville Health Systems

EKF Diagnostics Holdings plc announced the launch of its next generation sequencing technology PrecisionPath in partnership with Greenville Health Systems. For the first time patients will have wider access to affordable advanced NGS testing that can help doctors determine the most effective cancer treatments based on an individual's genetic profile. The launch of the PrecisionPath Colon by EKF's subsidiary Selah Genomics, follows a successful one year trial with GHS, one of cancer institutes in the US, and will be the first commercial NGS panel molecular test for invasive colon cancer priced under $1,000 with a target turnaround time of less than 7 days per reportable result. PrecisionPath can be used by oncologists nationally to identify the specific growth drivers for colon cancer in an individual based on their genetic make-up and to, ultimately, ensure the most effective therapy is used at all times during treatment. By identifying the cancer's specific susceptibility to available treatments, PrecisionPath will help oncologists select the most effective options for a patient based on the patient's tumor type. The advantage of the PrecisionPath Colon test panel is that it focusses on a key number of actionable biomarkers which provide maximum clinical utility at a more affordable cost. The panel provides a clear and concise report that differentiates between those genes with proven clinical utility and others under clinical trial investigation. As the body of evidence for clinical utility grows, reports will be updated accordingly, providing doctors with a means to routinely integrate genomic analysis into the everyday care of cancer patients. Initially PrecisionPath Colon will be available across GHS's oncology treatment centres. In Europe, it is predicted that there will be close to 450,000 new cases of colorectal cancer diagnosed in 2015. EKF will then expand the service throughout the US targeting oncologists and pathologists treating patients with invasive CRC. EKF intends to offer PrecisionPath™ in additional indications, including lung cancer, breast cancer and melanoma beginning in late 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LYF:GR €0.28 EUR -0.002

LYF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LYF.
View Industry Companies

Industry Analysis


Industry Average

Valuation LYF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.3x
Price/Book 1.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EKF DIAGNOSTICS HOLDINGS PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at